Patupilone in patients with pretreated metastatic/locally recurrent colorectal cancer: Results of the Phase II CINATRA trial

Investigational New Drugs

Volumn 31, Issue 5, 2013, Pages 1339-1344

  Moorcraft, S Y ^a   Chau, I ^a   Peckitt, C ^a   Cunningham, D ^a   Rao, S ^a   Yim, K L ^b   Walther, A ^c   Jackson, C G C A ^d   Stamp, G ^a   Webb, J ^a   Smith, G ^a   Gillbanks, A ^a   Swanton, C ^e  

^a Royal Marsden Hospital   (United Kingdom)

^b VELINDRE CANCER CENTRE   (United Kingdom)

^c UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF OTAGO   (New Zealand)

^e CRUK London Research Institute   (United Kingdom)

Author keywords

Colorectal cancer; Diarrhoea; Patupilone; Toxicity

Indexed keywords

DEXAMETHASONE; EPOTHILONE B; FLUOROPYRIMIDINE DERIVATIVE; IRINOTECAN; OXALIPLATIN; PREDNISOLONE;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; FEMALE; HUMAN; HYPOTENSION; INFECTION; LETHARGY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SKIN TOXICITY; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DIARRHEA; EPOTHILONES; FEMALE; HUMANS; LETHARGY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME; TUBULIN MODULATORS;

EID: 84884815635     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-9990-3     Document Type: Article

References (22)

1. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N (2010) Colorectal cancer. Lancet 375(9719):1030-1047. doi: 10.1016/S0140-6736(10)60353-4
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Annal Oncol Off J Eur Soc Med Oncol / ESMO 18(3):581-592. doi: 10.1093/annonc/mdl498
3. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D (2009) Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 9(7):489-499. doi: 10.1038/nrc2645
4. Swanton C, Tomlinson I, Downward J (2006) Chromosomal instability, colorectal cancer and taxane resistance. Cell cycle 5(8):818-823
5. Bystricky B, Chau I (2011) Patupilone in cancer treatment. Expert Opin Investigational Drugs 20(1):107-117. doi: 10.1517/13543784.2011.542148
6. Anand S, Penrhyn-Lowe S, Venkitaraman AR (2003) AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer cell 3(1):51-62
7. Melichar B, Casado E, Bridgewater J, Bennouna J, Campone M, Vitek P, Delord JP, Cerman J Jr, Salazar R, Dvorak J, Sguotti C, Urban P, Viraswami-Appanna K, Tan E, Tabernero J (2011) Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial. Br J Cancer 105(11):1646-1653. doi: 10.1038/bjc.2011.438
8. Iqbal S, El-Khoueiry AB, Yang D, Cole S, Boswell W, Shriki J, Ning Y, Agafitei RD, Menendez X, Lenz H (2010) A phase I study of celecoxib (C) and patupilone (EPO906) in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol Off J Am S Clin Oncol 28 (suppl; abstr 2533)
9. McSheehy P, Becquet M, Boisclair J, Bizot MN (2008) Prednisolone abrogates patupilone (EPO906)-induced diarrhoea in rats without impacting on patupilone PK or efficacy. Proc 20th EORTC-NCI-AACR Symp Mol Targets Cancer Ther EJC Suppl 6:451
10. Sridhar SS, Hotte SJ, Kollmannsberger CK, Mukherjee SD, Capier K, Barclay J, Adams L, Weber D, Chi KN (2010) Preventing patupilone-induced diarrhea with high-dose corticosteroids. J Clin Oncol Off J Am S Clin Oncol 28 (suppl; abstr e13069)
11. Kornblau S, Benson AB, Catalano R, Champlin RE, Engelking C, Field M, Ippoliti C, Lazarus HM, Mitchell E, Rubin J, Stiff PJ, Vokes E, Wadler S (2000) Management of cancer treatment-related diarrhea. Issues and therapeutic strategies. J Pain Symptom Manag 19(2):118-129
12. Wadler S, Benson AB 3rd, Engelking C, Catalano R, Field M, Kornblau SM, Mitchell E, Rubin J, Trotta P, Vokes E (1998) Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol Off J Am S Clin Oncol 16(9):3169-3178
13. Poplin E, Moore M, O'Dwyer P, Clarke S, Hill M, Sessa C, Rothermel J, Mull R, Miller J, L; R (2003) Safety and efficacy of EPO906 in patients with advanced colorectal cancer: A review of 2 phase II trials Proc Am Soc Clin Oncol 22 (abstr 1135)
14. Colombo N, Kutarska E, Dimopoulos M, Bae DS, Rzepka-Gorska I, Bidzinski M, Scambia G, Engelholm SA, Joly F, Weber D, El-Hashimy M, Li J, Souami F, Wing P, Engelholm S, Bamias A, Schwartz P (2012) Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J Clin Oncol Off J Am S Clin Oncol 30(31):3841-3847. doi: 10.1200/JCO.2011.38.8082
15. Hussain A, DiPaola RS, Baron AD, Higano CS, Tchekmedyian NS, Johri AR (2009) Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Annal Oncol Off J Eur Soc Med Oncol / ESMO 20(3):492-497. doi: 10.1093/annonc/mdn665
16. Reid TR, Takimoto CH, Verschraegen CF, Sarantopoulos J, Cheung W, Allen-Freda E, Li J, Xu Y, Ko J, Johri A (2008) Evaluation of safety, tolerability and pharmacokinetics (PK) of patupilone in patients (pts) with advanced solid tumors and varying degrees of hepatic function: An open-label phase I study. J Clin Oncol Off J Am S Clin Oncol 26: (May 20 suppl; abstr 2557)
17. Chi KN, Beardsley E, Eigl BJ, Venner P, Hotte SJ, Winquist E, Ko YJ, Sridhar SS, Weber D, Saad F (2012) A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a. Annal Oncol Off J Eur Soc Med Oncol / ESMO 23(1):53-58. doi: 10.1093/annonc/mdr336
18. Abrey LE, Wen P, Govindan R, Reimers H, Rigas JR, Robins HI, Allen-Freda E, Gao B, Ko J, Johri A (2008) Patupilone for the treatment of recurrent/progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): An open-label phase II study. J Clin Oncol Off J Am S Clin Oncol 26: (May 20 suppl; abstr 2033)
19. De Souza PL, Mellado B, Pfister C, Rosenthal M, Castellano DE, Weber D, Ferrara S, Shaik N, Tan E, S.G; P (2010) Randomized phase II trial of patupilone plus prednisone versus docetaxel plus prednisone in patients with chemotherapy-naïve, metastatic, castrate-resistant prostate cancer (CRPC). J Clin Oncol Off J Am S Clin Oncol 28 (suppl; abstr 4553)
20. Oehler C, Frei K, Rushing EJ, McSheehy PM, Weber D, Allegrini PR, Weniger D, Lutolf UM, Knuth A, Yonekawa Y, Barath K, Broggini-Tenzer A, Pruschy M, Hofer S (2012) Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial. Oncology 83(1):1-9. doi: 10.1159/000339152
21. Conlin AK, D'Andrea G, Hudis CA, Robson ME, Drullinsky P, Theodoulou M, Lis E, Kang TY, Peereboom DM, Seidman AD (2008) Phase II trial of patupilone in patients (pts) with breast cancer brain metastases (BCBM) progressing or recurring after whole brain radiation therapy (WBXRT) Journal of Clinical Oncology 26 (May 20 Suppl;1086)
22. Rubin EH, Rothermel J, Tesfaye F, Chen T, Hubert M, Ho YY, Hsu CH, Oza AM (2005) Phase I dose-finding study of weekly single-Agent patupilone in patients with advanced solid tumors. J Clin Oncol Off J Am S Clin Oncol 23(36):9120-9129. doi: 10.1200/JCO.2005.03.0981